In the April–June 2016 edition of Corporate Disputes, Dr. Gregory K. Bell discusses disputes in the healthcare and life sciences industry. In this roundtable discussion, the panel experts describe the underlying causes of recent disputes in the sector and highlight key cases. To read the article, click the link below.
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...